MedTrace Logo

Patients Referred to the Chronic Pain Unit for Palliative Treatment With Ozone Therapy Between 2022 and 2025

NCT05417737 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 105

Last updated 2025-09-02

No results posted yet for this study

Summary

The main objective of this study is to analyze the impact on the health-related quality of life of patients with refractory symptoms, who have been referred to the HUGCDN Chronic Pain Unit for adjuvant palliative treatment with ozone therapy between June-2022 and December-2025

Conditions

  • Radiation Toxicity
  • Chemotherapeutic Toxicity
  • Chemotherapy-induced Peripheral Neuropathy
  • Delayed Wound Healing
  • Chronic Pain
  • Refractory Pain

Interventions

OTHER

Ozone therapy

Systemic and/or local ozone administration. Dosage, frequency, and duration of ozone treatment will depend on the treated symptom and clinical evolution. Usually planned 40 sessions.

Sponsors & Collaborators

  • Fundacion Canaria Instituto de Investigacion Sanitaria de Canarias

    collaborator OTHER

  • Servicio Canario de Salud

    collaborator OTHER

  • Council of Gran Canaria

    collaborator OTHER

  • Red de Investigación en Servicios de Salud en Enfermedades Crónicas

    collaborator OTHER

  • Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias, Universidad de La Laguna

    collaborator UNKNOWN

  • Bernardino Clavo, MD, PhD

    lead OTHER

Principal Investigators

  • Bernardino Clavo, MD, PhyD · Dr. Negrín University Hospital, Las Palmas, Spain

  • Pedro G Serrano-Aguilar, MD, PhyD · Servicio de Evaluación. Servicio Canario de Salud. Spain

  • Bernardino Clavo, MD, PhyD · Dr. Negrín University Hospital, Las Palmas, Spain

  • Miguel A Caramés-Álvarez, MD · Dr. Negrín University Hospital, Las Palmas, Spain

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-15
Primary Completion
2025-12-31
Completion
2026-06-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05417737 on ClinicalTrials.gov